Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.39 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$68.77M
Enterprise Value$37.54
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.13Price Target Upside184.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt and positive equity provide structural financial flexibility versus highly leveraged peers. With ~$30M of assets and equity of ~$18.5M the company can fund near-term clinical activity and negotiate capital solutions from a stronger balance-sheet position if losses persist.
Clinical Enrollment Momentum & Site QualityConsistent and concentrated enrollment at high‑performing, KOL‑led sites reduces execution risk and supports trial timelines. Strong site engagement and investigator endorsement increase the likelihood of robust, usable data, improving the odds of a timely top-line read and regulatory filing.
Cash On Hand And Recent Tranche ClosedHaving $21.1M of cash and a recently closed $4.1M tranche materially extends runway versus cash-poor early‑stage peers. This funding buffer supports near‑term enrollment completion and regulatory activities, lowering immediate refinancing urgency while clinical milestones are executed.
Bears Say
Minimal Revenue And Large Net LossNear‑zero revenue with multi‑million net losses indicates the business is not yet generating sustainable commercial cash flows. Persistent operating losses deteriorate returns, pressure equity if continued, and mean the company remains dependent on external capital to fund operations and development.
Consistent Negative Operating Cash FlowA recurring negative operating cash flow of roughly $11M TTM shows structural cash burn that must be financed until revenue scales. Continuous negative free cash flow raises refinancing and dilution risk, and constrains strategic optionality such as additional trials or commercial investment.
Reliance On Conditional Financing TranchesDependence on milestone‑contingent funding ties liquidity to execution and timing. If enrollment, LPO or data timing slips, tranche conditions could fail, creating funding gaps that would force urgent capital raises, delay regulatory timelines, or require restructuring of development plans.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.39 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $68.77M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.13 (184.09% Upside)
$3.13 (184.09% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Stock 12 Month Forecast
Average Price Target
$3.13
▲(184.09% Upside)
Technical Analysis
Ownership Overview
6.01% Insiders
1.48% Mutual Funds
38.89% Other Institutional Investors
52.27% Public Companies and
Individual Investors